Failure of wild-type p53 gene therapy in human cancer cells expressing a mutant p53 protein

Gene Therapy

Volumn 6, Issue 1, 1999, Pages 22-33

  Vinyals, A ^a   Peinado, M A ^a   Gonzalez Garrigues, M ^a   Monzo M ^b   Bonfil, R D ^c   Fabra, A ^a  

^a Institut de Recerca Oncologica   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^c Centre de Estudios Farmacologicos y Botanicos   (Argentina)

Author keywords

Lacking wtp53 function; p53 mutation; Wtp53 gene therapy; Wtp53 transfer

Indexed keywords

ANTIBIOTIC G 418; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOASSAY; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CLONE; COLONY FORMING CELL; COLORECTAL CARCINOMA; CONTROLLED STUDY; EXCISION; GENE EXPRESSION; GENE INACTIVATION; GENE MUTATION; GENE THERAPY; GENETIC TRANSFECTION; HETEROZYGOSITY; HUMAN; HUMAN CELL; LATENT PERIOD; MOUSE; PRIORITY JOURNAL; REVERTANT; TUMOR GROWTH; YEAST;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; GENE EXPRESSION; GENE THERAPY; GENES, P53; HUMANS; MICE; MICE, NUDE; MUTATION; TRANSFECTION; TREATMENT FAILURE; TUMOR CELLS, CULTURED;

ANIMALIA; MUS MUSCULUS;

EID: 0032924995     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300786     Document Type: Article

References (59)

1. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878.
2. Sidransky D, Hollstein M. Clinical implications of the p53 gene. Annu Rev Med 1996; 47: 285-301.
3. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cel Biol 1993; 13: 301-306.
4. Knippschild U, Oren M, Deppert W. Abrogation of wild-type p53 mediated growth-inhibition by nuclear exclusion. Oncogene 1996; 12: 1755-1765.
5. Farmer G et al. Wild-type p53 activates transcription in vitro. Nature 1992; 358: 83-86.
6. Arrowsmith CH, Morin P. New insights into p53 function from structural studies. Oncogene 1996; 12: 1379-1385.
7. Buckbinder L, Talbott R, Seizinger BR, Kley N. Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes. Proc Natl Acad Sci USA 1994; 91: 10640-10644.
8. Canman CE, Chen CY, Lee MH, Kastan MB. DNA damage responses: p53 induction, cell cycle perturbations, and apoptosis. Cold Spring Harbor Symposia on Quantitative Biology 1994; 59: 277-286.
9. Kastan MB, Canman CE, Leonard CJ. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metast Rev 1995; 14: 3-15.
10. Pollock RE et al. Soft tissue sarcoma metastasis from clonal expansion of p53 mutated tumor cells. Oncogene 1996; 12: 2035-2039.
11. Symonds H et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 1994; 78: 703-711.
12. Donehower LA. Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. Biochim Biophys Acta - Rev Cancer 1996; 1242: 171-176.
13. Ullrich SJ, Anderson CW, Mercer WE, Appella E. The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 1992; 267: 15259-15262.
14. Marchetti A et al. P53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993; 53: 4665-4669.
15. Casey G et al. Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 1991; 6: 1791-1797.
16. Bacchetti S, Graham FL. Inhibition of cell proliferation by an adenovirus vector expression the human wild type p53 protein. Int J Oncol 1993; 3: 781-788.
17. Merlo GR et al. Growth suppression of normal mammary epithelial cells by wild-type p53. Breast Cancer: from Biology to Therapy. Ann NY Acad Sci 1993; 689: 108-113.
18. Merlo GR et al. Growth suppression of normal mammary epithelial cells by wild-type p53. Oncogene 1994; 9: 443-453.
19. Cirielli C et al. Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int J Cancer 1995; 63: 673-679.
20. Wang YS et al. Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Differ 1993; 4: 467-473.
21. Roemer K, Friedmann T. Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. Gene Therapy for Neoplastic Diseases. Ann NY Acad Sci 1994; 716: 265-282.
22. Shaw P et al. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495-4499.
23. Liu TJ et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995; 55: 3117-3122.
24. Yang CL, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995; 55: 4210-4213.
25. Radinsky R et al. Terminal differentiation and apoptosis in experimental lung metastases of human osteogenic sarcoma cells by wild type p53. Oncogene 1994; 9: 1877-1883.
26. Cajot JF et al. Growth suppression mediated by transfection of p53 in Hut292DM human lung cancer cells expressing endogenous wild-type p53 protein. Cancer Res 1992; 52: 6956-6960.
27. Noble JR et al. Effects of exogenous wild-type-p53 on a human lung carcinoma cell line with endogenous wild-type-p53. Exp Cell Res 1992; 203: 297-304.
28. Chen YM et al. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. Oncogene 1991; 6: 1799-1805.
29. Brenner L et al. Wild-type p53 tumor suppressor gene restores differentiation of human squamous carcinoma cells but not the response to transforming growth factor-beta. Cell Growth Differ 1993; 4: 993-1004.
30. Soddu S et al. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 1994; 83: 2230-2237.
31. Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastas Rev 1995; 14: 149-161.
32. Vojtesek B, Lane DP. Regulation of p53 protein expression in human breast cancer cell lines. J Cell Sci 1993; 105: 607-612.
33. Callahan R. p53 Mutations, another breast cancer prognostic factor. J Natl Cancer Inst 1992; 84: 826-827.
34. Lane DP. p53 and human cancers. Br Med Bull J 1994; 50: 582-599.
35. Tlsty TD et al. Genomic integrity and the genetics of cancer. Cold Spring Harbor Symposia on Quantitative Biology 1994; 59: 265-275.
36. Coleman WB, Tsongalis GJ. Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. Clin Chem 1995; 41: 644-657.
37. Pietenpol JA et al. Mammalian cells resistant to tumor suppressor genes. Proc Natl Acad Sci USA 1996; 93: 8390-8394.
38. Kyo E et al. Reduced tumorigenicity and cell motility of a gastric carcinoma cell line by introduction of wild-type p53 gene. Int J Oncol 1993; 3: 265-271.
39. Roth JA et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nature Med 1996; 2: 985-991.
40. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996; 88: 1442-1455.
41. Wigler M et al. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 1977; 16: 777-785.
42. Schmidt-Kastner PK, Jardine K, Cormier M, McBurney MW. Genes transfected into embryonal carcinoma stem cells are both lost and inactivated at high frequency. Somat Cell Mole Genet 1996; 22: 383-392.
43. Carder PJ et al. Mutation of the p53 gene precedes aneuploid clonal divergence in colorectal carcinoma. Br J Cancer 1995; 71: 215-218.
44. Usmani BA, Lunec J, Sherbet GV. DNA repair and repair fidelity in metastatic variants of the B16 murine melanoma. J Cell Biochem 1993; 51: 336-344.
45. Valgardsdottir R et al. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis. APMIS 1997; 105: 121-130.
46. Zhang W, Shay JW, Deisseroth A. Inactive p53 mutants may enhance the transcriptional activity of wild-type p53. Cancer Res 1993; 53: 4772-4775.
47. Milner J, Metcalf EA. Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991; 65: 765-774.
48. Levine AJ. 11th Klenk, Ernst Lecture - the p53 tumor suppressor gene and product. Biological Chemistry Hoppe-Seyler 1993; 374: 227-235.
49. Kern SE et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 1992; 256: 827-830.
50. Kimura M et al. Inability to induce the alteration of tumorigenicity and chemosensitivity of p53-null human pancreatic carcinoma cells after the transduction of wild-type p53 gene. Anticancer Res 1997; 17: 879-884.
51. Peinado MA, Malkhosyan S, Velazquez A, Perucho M. Isolation and characterization of allelic losses and gains in colorectal tumors by arbitrarily primed polymerase chain reaction. Proc Natl Acad Sci USA 1992; 89: 10065-10069.
52. Hartwell L, Weinert T, Kadyk L, Garvik B. Cell cycle checkpoints, genomic integrity, and cancer. Cold Spring Harbor Symposia on Quantitative Biology 1994; 59: 259-263.
53. Bertrand P et al. Increase of spontaneous intrachromosomal homologous recombination in mammalian cells expressing a mutant p53 protein. Oncogene 1997; 14: 1117-1122.
54. Lesoon-Wood LA et al. Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995; 6: 395-405.
55. Flaman JM et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci USA 1995; 92: 3963-3967.
56. Skenan P et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-1112.
57. Bonfil RD et al. Stimulation of angiogenesis as an explanation of matrigel-enhanced tumorigenicity. Int J Cancer 1994; 58: 233-239.
58. Mollinedo F, Martinez-Dalmau R , Modolell M. Early and selective induction of apoptosis in human leukemic cells by the alkyl-lysophospholipid ET-18-OCH3. Biochem Biophys Res Commun 1993; 192: 603-609.
59. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.